![](/img/cover-not-exists.png)
LBA-07 * Updated Results of the MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E mutated (BRAFm) metastatic colorectal cancer (mCRC)
Van Cutsem, E., Atreya, C., Andre, T., Bendell, J., Schellens, J., Gordon, M., McRee, A., Yoshino, T., Muro, K., ODwyer, P., Tabernero, J., Middleton, G., Ducreux, M., van Geel, R., Sidhu, R., Greger,Volume:
26
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdv262.07
Date:
June, 2015
File:
PDF, 100 KB
english, 2015